Biomedical Engineering Reference
In-Depth Information
206. Nowell S et al (2005) Association of genetic variation in tamoxifen-metabolizing enzymes
with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res
Treat 91:249-258
207. Wegman P et al (2005) Genotype of metabolic enzymes and the benefit of tamoxifen in post-
menopausal breast cancer patients. Breast Cancer Res 7:R284-R290
208. Wegman P et al (2007) Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and
tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 9:R7
209. Okishiro M et al (2009) Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not
associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast
cancer patients treated with adjuvant tamoxifen. Cancer 115:952-961
210. Lash T et al (2009) Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet
Oncol 10:825-833
211. Nowell S et al (2002) Association between sulfotransferase 1A1 genotype and survival of
breast cancer patients receiving tamoxifen therapy. J Natl Cancer Inst 94:1635-1640
212. Teft WA et al (2011) Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux
transporter P-glycoprotein (multidrug resistance 1). Drug Metab Dispos 39:558-562
213. Iusuf D et al (2011) P-glycoprotein (ABCB1) transports the primary active tamoxifen metab-
olites endoxifen and 4-hydroxytamoxifen and restricts their brain penetration. J Pharmacol
Exp Ther 337:710-717
214. Kiyotani K et al (2012) Pharmacogenomics of tamoxifen: roles of drug metabolizing enzymes
and transporters. Drug Metab Pharmacokinet 27(1):122-131
215. Partridge AH et al (2003) Nonadherence to adjuvant tamoxifen therapy in women with pri-
mary breast cancer. J Clin Oncol 21:602-606
216. McCowan C et al (2008) Cohort study examining tamoxifen adherence and its relationship to
mortality in women with breast cancer. Br J Cancer 99:1763-1768
217. Dezentje VO et al (2010) Effect of concomitant CYP2D6 inhibitor use and tamoxifen adher-
ence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol 28:2423-2429
218. Beer B et al (2010) Development and validation of a liquid chromatography-tandem mass
spectrometry method for the simultaneous quantification of tamoxifen, anastrozole, and
letrozole in human plasma and its application to a clinical study. Anal Bioanal Chem
398:1791-1800
219. Hershman DL et al (2010) Early discontinuation and nonadherence to adjuvant hormonal
therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28:4120-4128
220. Hershman DL et al (2011) Early discontinuation and non-adherence to adjuvant hormonal
therapy are associated with increased mortality in women with breast cancer. Breast Cancer
Res Treat 126:529-537
221. Kelly C et al (2010) Selective serotonin reuptake inhibitors and breast cancer mortality in
women receiving tamoxifen: a population based cohort study. BMJ 340:c693
222. Lammers LA et al (2010) The impact of CYP2D6-predicted phenotype on tamoxifen treat-
ment outcome in patients with metastatic breast cancer. Br J Cancer 103:765-771
223. Ahern TP et al (2009) No increase in breast cancer recurrence with concurrent use of tamoxifen
and some CYP2D6-inhibiting medications. Cancer Epidemiol Biomarkers Prev
18:2562-2564
224. Cronin-Fenton D et al (2010) Selective serotonin reuptake inhibitors and adjuvant tamoxifen
therapy: risk of breast cancer recurrence and mortality. Future Oncol 6:877-880
225. Lash T et al (2010) Breast cancer recurrence risk related to concurrent use of SSRI antide-
pressants and tamoxifen. Acta Oncol 49(3):305-312
226. Irvin WJ Jr et al (2011) Genotype-guided tamoxifen dosing increases active metabolite expo-
sure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol
29:3232-3239
227. Kiyotani K et al (2012) Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in
Japanese breast cancer patients. Breast Cancer Res Treat 131(1):137-145
228. Barginear MF et al (2011) Increasing tamoxifen dose in breast cancer patients based on
CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the anties-
trogenic activity score. Clin Pharmacol Ther 90:605-611
